Piper Sandler Keeps Their Buy Rating on Aligos Therapeutics (ALGS)

Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Aligos Therapeutics (ALGS – Research Report) today and set a price target of $7.00. The company’s shares closed yesterday at $0.66.

According to TipRanks, Rahimi is a 4-star analyst with an average return of 4.4% and a 36.69% success rate. Rahimi covers the Healthcare sector, focusing on stocks such as Soleno Therapeutics, Savara, and Madrigal Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Aligos Therapeutics with a $4.00 average price target.

Based on Aligos Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $2.68 million and a GAAP net loss of $27.89 million. In comparison, last year the company earned a revenue of $3.54 million and had a GAAP net loss of $21.89 million

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aligos Therapeutics (ALGS) Company Description:

Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH).